Kazia Therapeutics Limited (KZIA)
NASDAQ: KZIA · Real-Time Price · USD
12.63
-1.14 (-8.28%)
Sep 1, 2026, 4:00 PM EDT - Market closed
Kazia Therapeutics Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Operating Revenue | 0.04 | 0.04 | 2.31 | - | - | 15.18 |
Other Revenue | 1.86 | 1.79 | 0.17 | 0 | 0.01 | - |
| 1.9 | 1.83 | 2.48 | 0 | 0.01 | 15.18 | |
Revenue Growth | -24.15% | -26.28% | 248000.00% | -90.00% | -99.93% | 1436.54% |
Gross Profit | 1.9 | 1.83 | 2.48 | 0 | 0.01 | 15.18 |
Selling, General & Admin | 12.17 | 8.72 | 13.56 | 8.58 | 5.24 | 7.02 |
Research & Development | 8.04 | 7.33 | 17.38 | 15.56 | 20.17 | 14.54 |
Other Operating Expenses | - | - | - | - | -0.02 | -0 |
Operating Expenses | 20.21 | 16.05 | 30.94 | 24.15 | 25.39 | 21.56 |
Operating Income | -18.31 | -14.22 | -28.46 | -24.15 | -25.38 | -6.38 |
Interest & Investment Income | 0.2 | 0.07 | 0.01 | 0.02 | 0 | 0.04 |
Other Non Operating Income (Expenses) | 0.27 | -2.48 | 1.28 | - | - | - |
EBT Excluding Unusual Items | -17.84 | -16.62 | -27.17 | -24.12 | -25.38 | -6.34 |
Asset Writedown | -13.38 | -13.38 | - | - | - | - |
Other Unusual Items | 6.8 | 7.55 | 0.12 | 3.39 | - | -2.57 |
Pretax Income | -24.41 | -22.45 | -27.05 | -20.74 | -25.38 | -8.91 |
Income Tax Expense | -1.61 | -1.75 | -0.27 | -0.27 | -0.37 | -0.48 |
Earnings From Continuing Operations | -22.8 | -20.7 | -26.78 | -20.47 | -25.01 | -8.42 |
Net Income | -22.8 | -20.7 | -26.78 | -20.47 | -25.01 | -8.42 |
Net Income to Common | -22.8 | -20.7 | -26.78 | -20.47 | -25.01 | -8.42 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 2 | 1 | 1 | 0 | 0 | 0 |
Shares Outstanding (Diluted) | 2 | 1 | 1 | 0 | 0 | 0 |
Shares Change | 213.01% | 107.81% | 43.08% | 39.12% | 12.57% | 61.08% |
EPS (Basic) | -10.22 | -18.89 | -50.78 | -55.53 | -94.42 | -35.78 |
EPS (Diluted) | -10.22 | -18.89 | -50.78 | -55.53 | -94.42 | -35.80 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Free Cash Flow | -14.4 | -13.28 | -9.58 | -15.16 | -22.76 | -9.11 |
Free Cash Flow Per Share | -6.45 | -12.12 | -18.17 | -41.12 | -85.92 | -38.71 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -964.22% | -777.31% | -1147.20% | -2414600.00% | -253840.00% | -42.01% |
Profit Margin | -1200.90% | -1131.88% | -1079.32% | -2046500.00% | -250140.00% | -55.47% |
Free Cash Flow Margin | -758.36% | -725.97% | -386.17% | -1515600.00% | -227620.00% | -60.01% |
EBITDA | -17.84 | -13.28 | -26.59 | -22.28 | -23.52 | -5.11 |
EBITDA Margin | - | - | - | - | - | -33.68% |
D&A For EBITDA | 0.47 | 0.93 | 1.87 | 1.87 | 1.87 | 1.27 |
EBIT | -18.31 | -14.22 | -28.46 | -24.15 | -25.38 | -6.38 |
EBIT Margin | - | - | - | - | - | -42.01% |